- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.08. | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics raises SEK 28.3 million in oversubscribed unit issue | 3 | GlobeNewswire (USA) | ||
| 07.08. | Modus Therapeutics Holding AB: Modus Therapeutics publishes Interim report for the second quarter 2025 | 328 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 7 August 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the second quarter of 2025. The report is available on the company's website... ► Artikel lesen | |
| MODUS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.08. | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.08.2025 | 308 | Xetra Newsboard | Das Instrument 9YG NO0010955917 DEEP VAL.DRILL.AS NK -,10 EQUITY wird cum Kapitalmassnahme gehandelt am 06.08.2025 und ex Kapitalmassnahme am 07.08.2025 The instrument 9YG NO0010955917 DEEP VAL.DRILL.AS... ► Artikel lesen | |
| 01.08. | Modus Therapeutics Holding AB: Modus Therapeutics on track to initiate Part 2 of Phase IIa sevuparin study in CKD-related anemia | 296 | GlobeNewswire (Europe) | Stockholm, Sweden - 1 August 2025 - Modus Therapeutics Holding AB (publ) ("Modus") today announces that dose levels for Part 2 of its ongoing Phase IIa clinical study of sevuparin in patients with chronic... ► Artikel lesen | |
| 29.07. | Modus Therapeutics Holding AB: Extraordinary General Meeting in Modus Therapeutics Holding AB (publ) | 129 | GlobeNewswire (Europe) | Modus Therapeutics' Extraordinary General Meeting on 29 July 2025 resolved in accordance with the following:
To amend the company's articles of association in order to increase the limits of the company's... ► Artikel lesen | |
| 14.07. | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics completes enrollment in part 1 of its phase 2a study with sevuparin | 271 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has completed patient enrollment on schedule to part... ► Artikel lesen | |
| 08.07. | Modus Therapeutics Holding AB: Modus Therapeutics completes enrollment in Part 1 of the Phase IIa sevuparin study in chronic kidney disease with anemia | 172 | GlobeNewswire (Europe) | Stockholm, Sweden - 8 July 2025 - Modus Therapeutics Holding AB (publ) ("Modus") today announces that patient enrollment in Part 1 of its ongoing Phase IIa study evaluating sevuparin for the treatment... ► Artikel lesen | |
| 27.06. | Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million | 1 | GlobeNewswire (USA) | ||
| 14.05. | Modus Therapeutics Holding AB: Modus Therapeutics publishes Interim report for the first quarter 2025 | 444 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 14 May 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the first quarter of 2025. The report is available on the company's website... ► Artikel lesen | |
| 02.04. | Modus Therapeutics Holding AB: Modus Therapeutics opens second study site in ongoing Phase IIa CKD-anemia study | 155 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - April 2, 2025: Modus Therapeutics Holding AB ("Modus"), a company developing innovative treatments for patients with significant unmet medical needs, today announced the opening... ► Artikel lesen | |
| 20.02. | Modus Therapeutics Holding AB: Modus Therapeutics publishes year-end report for 2024 | 145 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 20 February 2025: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes the year-end report for 2024. The report is available as an attached document and on the company's... ► Artikel lesen | |
| 20.11.24 | Modus Therapeutics Holding AB: Modus Therapeutics publishes interim report for the third quarter 2024 | 132 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN - 20 November 2024: Modus Therapeutics Holding AB ("Modus Therapeutics") hereby publishes an interim report for the third quarter 2024. The report is available as an attached document... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NANOREPRO | 1,720 | -3,37 % | Original-Research: NanoRepro AG (von GBC AG): Kaufen | Original-Research: NanoRepro AG - von GBC AG
09.10.2025 / 12:00 CET/CEST
Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group.
Für den Inhalt der Mitteilung bzw.... ► Artikel lesen | |
| MARINOMED BIOTECH | 19,150 | +1,86 % | Marinomed: Neue Basis für Wachstum | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC fußt die für das Jahr 2025 prognostizierte deutliche Umsatzsteigerung bei der Marinomed Biotech AG auf Earn-outs im Rahmen... ► Artikel lesen | |
| REPLENISH NUTRIENTS | 0,068 | 0,00 % | Replenish Nutrients secures licensing deal with MJ Ag Solutions Ltd | ||
| SANA BIOTECHNOLOGY | 5,585 | 0,00 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression Six-Month Patient Follow-up Results Demonstrate... ► Artikel lesen | |
| I-MAB | 4,160 | +4,52 % | H.C. Wainwright bestätigt Kaufempfehlung für I-Mab nach positiven Krebsdaten | ||
| GENEURO | 0,031 | -19,49 % | GeNeuro SA Postpones Publication of June 30, 2025 Half-Yearly Financial Report | Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces the postponement of... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 69,91 | 0,00 % | Biotech-Boom: Novartis übernimmt Avidity Biosciences für 12 Milliarden US$ | Der Schweizer Pharmakonzern Novartis hat einen bedeutenden Schritt in der Erweiterung seines Portfolios gemacht. Mit der Übernahme des US-Biotechnologieunternehmens Avidity Biosciences stärkt Novartis... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,290 | +0,50 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| ARCUTIS BIOTHERAPEUTICS | 25,010 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results | Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and... ► Artikel lesen | |
| 89BIO | 14,835 | 0,00 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| RELAY THERAPEUTICS | 7,520 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates | Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 199,36 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 14,320 | 0,00 % | Amylyx, Amneal, And Argenx Hit 52-Week Highs Amid Drug Pipeline Momentum And Strategic Catalysts | AMSTERDAM (dpa-AFX) - Multiple biotech companies are gaining traction as they hit fresh 52-week highs, driven by clinical advancements, regulatory milestones, and strategic funding initiatives.... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 11,970 | -2,52 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | EMERYVILLE, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,910 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen |
Das Unternehmen MODUS THERAPEUTICS HOLDING AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,024 Euro und damit +1,69 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MODUS THERAPEUTICS HOLDING AB finden Sie auf Wallstreet Online.